PE firm Advent names its India API, CDMO platform as Cohance Lifesciences

The US-based PE firm which is betting on India pharma, said that it intends to add more assets in the future with the vision to become one of the top three merchant API and CDMO companies in India. "The setting up of Cohance Lifesciences is significant, as it would help in establishing a unified new brand identity for the API and CDMO platform, to better reflect its vision and operating philosophy," Advent said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PrxJiGS
via IFTTT